Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors

被引：0
|
作者：
Abou Jokh Casas, E. [1 ]
Pombo Pasin, M. D. [1 ]
Pubul Nunez, V. [1 ]
Garrido Pumar, M. [1 ]
Blanco Freire, M. N. [1 ]
Cabezas, J. [1 ]
Cameselle, J. [1 ]
Berrios, M. [1 ]
Argibay, S. [1 ]
Ruibal Morell, A. [1 ]
机构：
[1] Complejo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0742
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [31] Establishing a clinical dosimetry protocol for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Bissell, S.
    Ross, E.
    McMeekin, H.
    Seal, E.
    Ogunwale, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S106 - S106
  • [32] Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
    Kalshetty, Ashwini
    Ramaswamy, Anant
    Ostwal, Vikas
    Basu, Sandip
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1143 - 1149
  • [33] Polish Multicenter Experience with Tandem Peptide Receptor Radionuclide Therapy Using 90Y/177Lu-DOTATATE in Neuroendocrine Tumors
    Kunikowska, J.
    Zemczak, A.
    Kolodziej, M.
    Gut, P.
    Lon, I
    Pawlak, D.
    Mikolajczak, R.
    Kaminski, G.
    Ruchala, M.
    Kos-Kudla, B.
    Krolicki, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 216 - 216
  • [34] Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Minczeles, Noemie S.
    de Herder, Wouter W.
    Feelders, Richard A.
    Verburg, Frederik A.
    Hofland, Johannes
    Brabander, Tessa
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 40 - 46
  • [35] Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action
    Assadi, Majid
    Rekabpour, Seyed Javad
    Amini, Abdullatif
    Dadgar, Habibollah
    Nemati, Reza
    Gholamrezanezhad, Ali
    Nabipour, Iraj
    Jafari, Esmail
    Ahmadzadehfar, Hojjat
    MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2021, 30 (02) : 107 - 109
  • [36] Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy
    Abbott, Amanda
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2018, 46 (03) : 245 - 246
  • [37] Efficacy of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Inoperable/Metastatic, Progressing Neuroendocrine Tumors: Results of Our First Clinical Experience
    Gunalp, B.
    Ucgun, A.
    Goker, U.
    Mahmudov, S.
    Ince, S.
    Alagoz, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S641 - S642
  • [38] Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE
    Pirisino, Riccardo
    Filippi, Luca
    D'Agostini, Antonio
    Bagni, Oreste
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (11) : E692 - E695
  • [39] Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Bergsma, Hendrik
    van Lom, Kirsten
    Raaijmakers, Marc H. G. P.
    Konijnenberg, M.
    Kam, B. L. Boen L. R.
    Teunissen, Jaap J. M.
    de Herder, Wouter W.
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) : 452 - 458
  • [40] Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with 177Lu-DOTATATE
    Rahul V. Parghane
    Sandip Basu
    Journal of Nuclear Cardiology, 2020, 27 : 340 - 341
12345